|
- Paper by Dr Nigel Speight and Helen Brownlie: The findings of . . .
The findings of controlled trials on use of intravenous immunoglobulin G (IV IgG) to treat myalgic encephalomyelitis chronic fatigue syndrome (ME CFS) are generally viewed as representing mixed results
- DISCUSSION: Internal tremor in Long COVID may be a symptom of . . .
Results: Our patient’s IT improved significantly after intravenous saline infusions, but there was no effect on IT with oral hydration, increased oral sodium chloride intake, neuropathic pain medications, muscle relaxants, or medications used for the treatment of POTS
- Patient-reported treatment outcomes in ME CFS and long COVID, July 8 . . .
Intravenous immunoglobulin is being looked at for dysautonomia POTS as well No, it is not necessarily due to immunoglobulin deficiency, although some of us have that It suppresses autoimmunity by overwhelming the "bad" autoantibodies with good antibodies
- Search - Phoenix Rising ME CFS Forums
I normally do 1 L (of Hartmann's) in 40-70 minutes, depending on how fast my vein is going on that day lol I find the faster the better in that I have POTS OI and I sit up for the infusions, so I feel more worn out the longer they take
- The Times 21st Oct 2024: Severely ill patient with ME begs for home . . .
A severely ill patient with myalgic encephalomyelitis is begging a hospital to facilitate intravenous feeding at home, fearing she will otherwise die of malnutrition Karen Gordon, 38, has been suffering with the condition, also known as chronic fatigue syndrome, since she was ten after falling ill with a virus
- DISCUSSION: Cyclophosphamide in ME CFS Part A:an Open Label Phase-II . . .
Part A: an Open Label Phase-II Study With Six Intravenous Cyclophosphamide Infusions Four Weeks Apart, and Follow-up for 12 Months It seems that the study is due to be finished in November 2016 That means we probably will have results approximately 1 year before the Rituximab phase 3 is published
- Update in the understanding of New Daily Persistent Headache, 2023
Intravenous lidocaine Marmura et al in a retrospective study, studied 68 intractable cases with chronic daily headache including 12 NDPH patients were treated with IV lidocaine 25 4% of subjects exhibited a complete response and 57 1% exhibited partial response They suggested that patients with NDPH may benefit from IV lidocaine treatment
- Dr Chia finds enterovirus ME CFS patients given the antiviral . . .
A new study by Dr John Chia finds that 75% of enterovirus ME CFS patients who were given a 5 to 10 day course of the intravenous antiviral remdesivir obtained remission within 2 to 6 weeks of this treatment, and remained in remission for a period of time ranging from 6 weeks to 9 months This
|
|
|